S&P 500

5.473,29

0,07%

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

ENLV

Enlivex Therapeutics (ENLV)

Enlivex Therapeutics Ltd

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ENLV

1 2 3 4 5 6 7 8 9 Next >>

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
24/06/2024	14h00	GlobeNewswire Inc.	Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis	NASDAQ:ENLV	Enlivex Therapeutics Ltd
20/06/2024	14h04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ENLV	Enlivex Therapeutics Ltd
20/06/2024	14h00	GlobeNewswire Inc.	Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25	NASDAQ:ENLV	Enlivex Therapeutics Ltd
17/06/2024	14h03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ENLV	Enlivex Therapeutics Ltd
17/06/2024	14h00	GlobeNewswire Inc.	Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis	NASDAQ:ENLV	Enlivex Therapeutics Ltd
14/06/2024	22h30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ENLV	Enlivex Therapeutics Ltd
03/06/2024	14h05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ENLV	Enlivex Therapeutics Ltd
03/06/2024	14h00	GlobeNewswire Inc.	Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis	NASDAQ:ENLV	Enlivex Therapeutics Ltd
29/05/2024	22h20	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ENLV	Enlivex Therapeutics Ltd
29/05/2024	22h15	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ENLV	Enlivex Therapeutics Ltd
29/05/2024	22h15	GlobeNewswire Inc.	Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering	NASDAQ:ENLV	Enlivex Therapeutics Ltd
28/05/2024	14h13	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ENLV	Enlivex Therapeutics Ltd
28/05/2024	14h12	GlobeNewswire Inc.	Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering	NASDAQ:ENLV	Enlivex Therapeutics Ltd
29/04/2024	14h00	GlobeNewswire Inc.	Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events	NASDAQ:ENLV	Enlivex Therapeutics Ltd
22/04/2024	14h00	GlobeNewswire Inc.	Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis	NASDAQ:ENLV	Enlivex Therapeutics Ltd
16/04/2024	22h55	AllPennyStocks.com	Yet Another Biotech Stock Has Found Success During Tuesday's Session	NASDAQ:ENLV	Enlivex Therapeutics Ltd
16/04/2024	13h50	GlobeNewswire Inc.	Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis	NASDAQ:ENLV	Enlivex Therapeutics Ltd
11/04/2024	20h58	GlobeNewswire Inc.	Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis	NASDAQ:ENLV	Enlivex Therapeutics Ltd
11/04/2024	14h05	GlobeNewswire Inc.	Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis	NASDAQ:ENLV	Enlivex Therapeutics Ltd
07/02/2024	14h02	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ENLV	Enlivex Therapeutics Ltd
07/02/2024	14h00	GlobeNewswire Inc.	Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method	NASDAQ:ENLV	Enlivex Therapeutics Ltd
22/01/2024	14h00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ENLV	Enlivex Therapeutics Ltd
17/01/2024	14h02	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ENLV	Enlivex Therapeutics Ltd
17/01/2024	14h00	GlobeNewswire Inc.	Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis	NASDAQ:ENLV	Enlivex Therapeutics Ltd
20/12/2023	14h01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ENLV	Enlivex Therapeutics Ltd
09/11/2023	22h30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ENLV	Enlivex Therapeutics Ltd
07/11/2023	22h30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ENLV	Enlivex Therapeutics Ltd
02/11/2023	21h30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ENLV	Enlivex Therapeutics Ltd
26/10/2023	22h30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ENLV	Enlivex Therapeutics Ltd
18/09/2023	14h00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ENLV	Enlivex Therapeutics Ltd